1. Introduction
===============

Bullous pemphigoid (BP) is the most common bullous autoimmune disease and is recognized as the prototype of subepidermal autoimmune blistering disorders (SABD). BP, like pemphigus vulgaris, occurs in older adults more commonly than in younger individuals with typical onset between 60 and 80 years of age.^\[[@R1]\]^

Tense blisters are a characteristic feature of SABD, owing to basement membrane zone disruption and consequent splitting of the skin. SABD are immunologically characterized by the presence of autoantibodies directed against basement membrane zone antigens and BP is defined by IgG antibodies against bullous pemphigoid antigen 180 (BP180), the most common antigenic target in the disease, and bullous pemphigoid antigen 230 (BP230).

When BP is suspected, an accurate diagnostic approach is essential to rule out differential diagnoses, as blistering disorders share clinical presentation. Laboratory diagnosis relies on direct immunofluorescence (DIF), which examines linear antibody or complement deposition at the basement-membrane zone of the skin on a biopsy sample, and serologic tests, namely indirect immunofluorescence (IIF) studies and ELISA, for the detection of circulating antibodies on the serum.

DIF is considered the gold standard for diagnosis and should be performed on a skin biopsy from perilesional tissue.^\[[@R2]\]^ Serologic studies provide additional information that is useful for diagnosis and therapeutic management in most patients.^\[[@R3]\]^

Furthermore, serum testing combining the 2 techniques of IIF and ELISA supports a clinical diagnosis of BP when DIF is negative in a patient with clinical and histopathologic findings that are consistent with bullous pemphigoid.^\[[@R4]\]^

BP is prevalent in elderly adults and, according to the experience of the authors, is most common in very old people. Such a subset of patients stands out for a high prevalence of comorbidities that contraindicate surgical biopsy procedures. In these cases, serum testing procedures are ultimately essential when adequate biopsy tissue may not be obtained.^\[[@R2]\]^

It is accepted that serum testing in SABD may be performed on serum centrifuged from blood samples as well as on blister fluid. Autoantibodies, and other inflammatory mediators including interleukins and cytokines, are detected in blister fluid, a finding consistent with a localized inflammatory process.^\[[@R5]--[@R7]\]^

In 2004, Daneshpazhooh et al performed IIF on blister fluid to compare antibody titers with those of serum in patients with SABD.^\[[@R8]\]^ The authors conducted serum testing on salt-split skin to enhance sensitivity to the test.^\[[@R9],[@R10]\]^ 88% (22 out of 25) BP patients were positive for IgG in both serum and blister fluid, with an equivalent IgG titer in 16 out of 22 patients and 1 or 2 dilutions lesser in the remaining patients. No significant difference between serum and blister fluid antibody titers (*P* \> .05) emerged and the authors concluded that IIF sensitivity on blister fluid is no more than that on serum and that the blister fluid of patients with SABD can be used for diagnosis with IIF.

Antibody titer in blister fluid is equivalent or lesser than in serum since antibody production in BP takes place systemically and, subsequently, immunoglobulins diffuse locally to blister fluid. The performance of IIF on blister fluid as an alternative to serum has been previously proposed for the diagnosis of SABD^\[[@R11]\]^ in patients with poor venous access, a feature common in the very elderly adults that are most frequently affected by BP.

The purpose of this study was to detect BP180 autoantibody in blister fluid from BP patients with poor venous access, not allowing for adequate blood samples, using Biochip-based IIF. To assess the performance of our Biochip assay, the results were compared to those obtained from ELISA.

A Biochip-based indirect immunofluorescence technique for the determination of BP180 autoantibodies has been recently described,^\[[@R12]\]^ however, there are no studies concerning the use of blister fluid as substrate for this novel approach.

Commercially available ELISA antigen-specific serologic testing for BP are widely employed for the detection of circulating IgG against BP180 and BP230 in blood serum and their role in blister fluid detection of these autoantibodies has been demonstrated, with reported sensitivity of 61,5% for anti BP180 ELISA.^\[[@R13]\]^ IgG BP180 antibody levels have been demonstrated to correlate with disease activity in BP,^\[[@R14]\]^ and several clinicians also measure response to therapy with ELISA. Finally, assessing the reliability of testing on blister fluid may avoid consecutive blood withdrawals in fragile patients with poor venous access.

2. Methods
==========

This pilot study included 13 patients of Caucasian ethnicity, 4 females and 9 males. The diagnosis of BP was established by positive DIF in patients with typical clinical phenotype and for which adequate venous access could not be obtained. Blister fluid was collected from each of the 13 individuals before initiating treatment and all sera were anonymized prior to testing. Analyses were conducted by experienced staff members of our Dermatology Unit, using both the Biochip antibody detection technology and target antigen-specific ELISA assay.

2.1. Biochip indirect immunofluorescence
----------------------------------------

Biochip assay is a test devised for in vitro detection of human antibodies and investigates, like other indirect immunofluorescence techniques, the presence of basement membrane zone antibodies in the serum of patients with BP. Unlike traditional indirect immunofluorescence, where components of an epithelial specimen that are not from the patient are applied to microscope slides, Biochip substrates are applied to thin glass slides that are mechanically cut into millimeter-sized fragments in a fashion comparable to the manufacture of microchips in the electronics industry. Such production method yields large standardized batches of substrate, with minimal variations in quality. Biochips are then glued side by side onto microscope slides employing automated assembly equipment. The small scale of Biochip fragments is suitable for the assembly of multiparametric Biochip mosaics for the simultaneous incubation of a single fluid sample on the required number of substrates and may be customized to include frozen tissue sections of human 1 M salt-split skin or monkey esophagus, desmoglein-1 and desmoglein-3 expressing cells, BP230-gC-expressing cells and recombinant tetrameric BP180-NC16A spots.^\[[@R15]\]^

Slides mounting the Biochips are first incubated with patient samples at 1:10 dilution for 30 minutes at room temperature, then rinsed and immersed in wash buffer solution for 5 minutes. In a second incubation step, fluorescein isothiocyanate (FITC)-conjugated goat anti-human IgA/G antibodies to detect bound antibodies are applied for 30 minutes at room temperature, followed by washing as before. Results are visually examined through conventional fluorescence microscopy. A positive biochip reaction occurs when specific antibodies attach to the tested antigens and subsequently become stained with fluorescein-labelled anti-human immunoglobulins (Euroimmun Italy, Padua, Italy)

The substrate for the detection of BP180 autoantibodies on blister fluid used in this study was recombinant tetrameric BP180-NC16A spotted on cover glass then fragmented into Biochips and was supplied by Euroimmun Italy (Fig. [1](#F1){ref-type="fig"}).

![Detection of BP180 autoantibodies using recombinant tetrameric BP180-NC16A. spotted on cover glass. A positive reactivity is characterized by rhomboidal-shaped fluorescent microdrops.](medi-98-e14514-g001){#F1}

The extracellular membrane-proximal domain of BP180, which is designated as NC16A, has been recognized, using in vitro and in vivo models, to harbor target antigen sites of pathogenic autoantibodies of BP and is considered an appropriate substrate for the detection of BP180 antibodies.^\[[@R16]--[@R18]\]^

2.2. ELISA enzyme-linked immunosorbent assay
--------------------------------------------

ELISA is currently the preferred technique for assessing basal membrane zone antibodies in the diagnosis of bullous pemphigoid and other blistering disorders.^\[[@R19]\]^ ELISAs for BP antibodies are currently commercially available and detect circulating IgG against BP180, which is the most common antigenic target.

In this study, ELISA for the detection of anti-BP180 antibodies employed monomeric recombinant NC16A domain expressed as a GST fusion protein and was performed according to the manufacturer\'s instructions ("MBL Medical & Biological Laboratories Co., Ltd."). The cut-off value for a positive result was set at 9 U/mL.^\[[@R20]\]^

The anti-BP180 ELISA test is a validated diagnostic tool, with reported sensitivity and specificity of 89.0% and 94.8%, respectively, and is also used to support treatment decisions as antibody levels correlate with disease activity, especially in patients who are free from skin lesions. In 2007 a new ELISA system using recombinant tetrameric NC16A domains was developed, showing comparable results, with 89.8% sensibility and 97.8% specificity.^\[[@R21]\]^

This was a retrospective archive study hence we did not seek ethical approval.

3. Results
==========

Biochip detected autoantibodies reactive to BP180 in the blister fluid of 10 out of 13 patients with clinical suspect of bullous pemphigoid. The results paralleled those obtained by means of ELISA assay. Negative results with Biochip were observed in 3 cases out of 13 and correlated to low antibody titers on ELISA. The 2 alternative assays scored equivalent specificity of 76,9% and no discordant result was observed (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

###### 

Results at the time of diagnosis. ELISA values are expressed as Unit/mL.
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###### 

Summary of results in BP patients.
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4. Discussion
=============

The aim of this pilot study was to evaluate the potential diagnostic value of testing BP patient blister fluid with a Biochip-based indirect immunofluorescence technique for the detection of autoantibodies against BP180 and to assess its performance in relation to ELISA test results on the same samples. Blister fluid is a biologic sample that may be easily obtained, once or consecutively, from patients with BP and other cutaneous autoimmune blistering disorders. Serum components, which are produced systemically in SABD and enter blood circulation, diffuse to local sites of the inflammatory process so that autoantibodies and other inflammatory mediators may be detected in skin lesions.^\[[@R5]--[@R7]\]^ This constitutes the basis for performing serum testing in SABD on centrifuged blister fluid, an alternative to blood samples.

We propose a non-invasive technique as a safe and tolerable test in elderly patients with poor venous access and for which a biopsy procedure may not be performed.

The use of biochip-based indirect immunofluorescence for the determination of BP180 autoantibodies has been previously described and the technique is proven to be a specific and sensitive alternative to ELISA testing in the serum diagnosis of BP.^\[[@R12],[@R22]\]^

A previous study evaluated blister fluid from BP patients as substrate for IIF in comparison to serum diagnosis on blood samples,^\[[@R8]\]^ but our investigation is the first in literature to use a Biochip approach on blister fluid samples. We also used the same biofluid samples to perform a direct comparison between the Biochip and ELISA, showing a perfect correlation of the results for BP180 autoantibodies in our group of 13 patients.

ELISA is currently the preferred technique for detecting basement membrane zone antibodies in SABD, as it holds numerous advantages: it is a readily reproducible method that allows simultaneous analysis of multiple samples in limited time and, notably, provides quantitative results. Levels of IgG BP180 NC16A antibody are known to correlate with disease activity and current clinical practice relies on ELISA not only to support diagnosis but also to measure response to therapy.^\[[@R14]\]^ A drawback to the test is its high cost and false negative results due to the recombinant protein not containing all epitopes present in vivo.

Up to 10% of patients with BP are thought to bear antibodies to epitopes of BP180 and BP230 that are not recognized by commercially available ELISA tests. In support to this hypothesis is the observation of strong reactivity by immunoblot to BP180 epitopes outside of NC16A domain in patients testing negative to ELISA for BP180 NC16A.^\[[@R23]\]^ This may explain the negative results scored by 3 patients of our study with ELISA and Biochip, being detection limited to antibody specificities within the NC16A domain.

Biochip technique may outdo the limitations of ELISA offering an alternative affordable even for a small laboratory, as the test is about 50% cheaper than ELISA and the execution is simple and fast, taking about 100 minutes. Incubation steps all take place at room temperature, reagent and serum consumption is 50 μL per test field and only standard fluorescence microscopy equipment is required for the visual interpretation of results.

Furthermore, unlike ELISA commercial kits that are specific for a single parameter, the Biochip approach is devised for the simultaneous detection of different antibody specificities on a panel of substrates in a single incubation procedure and a custom Biochip mosaic may be tailored according to requirements. For this reason, the test is suitable for initial screening in the diagnostic workup of BP and other SABDs, reserving ELISA to confirm doubtful results.

The main limitation of the Biochip approach is that it does not provide a quantitative result, although a semi-quantitative analysis may be performed measuring the highest of serial dilutions of the tested serum that still produces immunofluorescence.

5. Conclusions
==============

In conclusion, our study suggests that a Biochip-based test on blister fluid is an appropriate initial approach to the diagnostic workup of patients with suspected BP. Our results, though the size of our sample was limited, support the use of blister fluid as an alternative to serum for IIF in fragile elderly patients with poor venous access. The Biochip IIF technique is proposed as a simple standardized approach to be readily implemented even in small labs. Finally, future immunologic studies testing Biochip mosaics on the bulla, the primary skin lesion of SABD, will provide new insight into the pathogenesis of bullous disorders.
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